Tumor infiltration of CD8+ T cells was also significantly improved in all three treatment groups (Fig. 5e and Supplementary Fig. 14a), along with a significantly increased CD8+/FoxP3+ Treg cell ratio (Fig. 5f and Supplementary Fig. 14b). This evidence concerns the gene FOXP3 and neoplasm.